Back to Results
First PageMeta Content
Triazines / Orphan drugs / Azacitidine / lactams / Myelodysplastic syndrome / Decitabine / Hypomethylating agent / Lenalidomide / Acute myeloid leukemia / Medicine / Oncology / Nucleosides


Abst. No. Outcomes of Intermediate or High Risk Myelodysplastic Syndromes (MDS) Patients Post Azacitidine and/or Decitabine Treatment Failures with SGI-110, a Novel Second Generation Hypomethylating Agent (HMA)
Add to Reading List

Open Document

File Size: 263,44 KB

Share Result on Facebook
UPDATE